Mitotic count can predict tamoxifen benefit in postmenopausal breast cancer patients while Ki67 score cannot

BACKGROUND: Controversy exists for the use of Ki67 protein expression as a predictive marker to select patients who do or do not derive benefit from adjuvant endocrine therapy. Whether other proliferation markers, like Cyclin D1, and mitotic count can also be used to identify those estrogen receptor...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:BMC Cancer
Glavni autori: Beelen, Karin, Opdam, Mark, Severson, Tesa, Koornstra, Rutger, Vincent, Andrew, Wesseling, Jelle, Sanders, Joyce, Vermorken, Jan, van Diest, Paul, Linn, Sabine
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2018
Teme:
Research Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6057037/
https://ncbi.nlm.nih.gov/pubmed/30041599
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-018-4516-1
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items